Stakeholder Input
Authors
Related Organizations
- Pages
- 195
- Published in
- Canada
CADTH Reimbursement Review - Olaparib (Lynparza) - Sponsor: AstraZeneca Canada Inc. Therapeutic area: gBRCAm, HER2-negative, high-risk early breast cancer
9 May 2023
Accessing this content requires a membership
If your institution is a member, please log into Policy Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.
Add to list
Citation
Health, C., 2023. CADTH Reimbursement Review - Olaparib (Lynparza) - Sponsor: AstraZeneca Canada Inc. Therapeutic area: gBRCAm, HER2-negative, high-risk early breast cancer, Canadian Agency for Drugs and Technologies in Health.
Canada.
Retrieved from https://coilink.org/20.500.12592/b1dgw2 on 23 Nov 2024. COI: 20.500.12592/b1dgw2.
Full-page Screenshot
